Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 9733503.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties. Like clinically used antidepressant and anxiolytic drugs, substance P antagonists suppressed isolation-induced vocalizations in guinea pigs. In a placebo-controlled trial in patients with moderate to severe major depression, robust antidepressant effects of the substance P antagonist MK-869 were consistently observed. In preclinical studies, substance P antagonists did not interact with monoamine systems in the manner seen with established antidepressant drugs. These findings suggest that substance P may play an important role in psychiatric disorders.
Medical subject headings
- Antidepressive Agents, Second-Generation
- Depressive Disorder
- Morpholines
- Neurokinin-1 Receptor Antagonists
- Substance P